循环microRNA可预测静脉血栓栓塞症后的复发和死亡
该研究纳入急性VTE队列181名参与者和基于人群队列中302名有VTE病史者,采用下一代测序检测EDTA血浆循环miRNA,发现50个miRNA与复发VTE或死亡相关(交叉验证C指数0.65),加权miRNA评分可预测8年随访结局(HR 2.39;95%CI 1.98-2.88;P<.0001),并在独立验证队列中验证20个miRNA(评分OR 3.47;95%CI 2.37-5.07;P<.0001;交叉验证AUC 0.61)。
要点
- 循环miRNA可预测VTE后数年内的复发或死亡风险,覆盖急性和慢性期。
- 发现队列中50个miRNA与复发VTE或死亡相关,加权评分预测8年随访结局HR 2.39。
- 验证队列证实20个miRNA及评分与结局相关,交叉验证AUC 0.61。
核心结论
- 循环miRNA在急性和慢性期均可预测VTE后数年内的复发或死亡风险。
研究设计与样本
- 研究数据来自急性VTE队列研究的181名参与者和基于人群队列中有VTE病史的302名个体。
- 对EDTA血浆样本进行下一代测序以检测循环miRNA,终点为复发VTE或死亡。
- 采用惩罚回归识别与结局相关的miRNA特征,并在基于人群的队列中进行验证。
主要发现
- 后处理后在队列中共检测到1950个miRNA。
- 发现队列中50个miRNA与复发VTE或死亡相关(交叉验证C指数0.65)。
- 加权miRNA评分预测8年随访期结局(HR 2.39;95%CI 1.98-2.88;P<.0001)。
- 独立验证队列验证了20个miRNA(评分OR 3.47;95%CI 2.37-5.07;P<.0001;交叉验证AUC 0.61)。
- 主成分分析揭示5个miRNA网络与临床表型和结局有不同关系,靶基因映射提示通过参与纤溶相关信号通路的转录因子和激酶调控。
关键数值与推荐
- 发现队列:50个miRNA与复发VTE或死亡相关,交叉验证C指数0.65。
- 加权miRNA评分预测8年随访结局:HR 2.39(95%CI 1.98-2.88;P<.0001)。
- 验证队列:20个miRNA被验证,评分OR 3.47(95%CI 2.37-5.07;P<.0001),交叉验证AUC 0.61。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recurrent events frequently occur after venous thromboembolism (VTE) and remain difficult to predict based on established genetic, clinical, and proteomic contributors. The role of circulating microRNAs (miRNAs) has yet to be explored in detail. OBJECTIVES: To identify circulating miRNAs predictive of recurrent VTE or death, and to interpret their mechanistic involvement. METHODS: Data from 181 participants of a cohort study of acute VTE and 302 individuals with a history of VTE from a population-based cohort were investigated. Next-generation sequencing was performed on EDTA plasma samples to detect circulating miRNAs. The endpoint of interest was recurrent VTE or death. Penalized regression was applied to identify an outcome-relevant miRNA signature, and results were validated in the population-based cohort. The involvement of miRNAs in coregulatory networks was assessed using principal component analysis, and the associated clinical and molecular phenotypes were investigated. Mechanistic insights were obtained from target gene and pathway enrichment analyses. RESULTS: A total of 1950 miRNAs were detected across cohorts after postprocessing. In the discovery cohort, 50 miRNAs were associated with recurrent VTE or death (cross-validated C-index, 0.65). A weighted miRNA score predicted outcome over an 8-year follow-up period (HRSD, 2.39; 95% CI, 1.98-2.88; P < .0001). The independent validation cohort validated 20 miRNAs (ORSD for score, 3.47; 95% CI, 2.37-5.07; P < .0001; cross-validated-area under the curve, 0.61). Principal component analysis revealed 5 miRNA networks with distinct relationships to clinical phenotype and outcome. Mapping of target genes indicated regulation via transcription factors and kinases involved in signaling pathways associated with fibrinolysis. CONCLUSION: Circulating miRNAs predicted the risk of recurrence or death after VTE over several years, both in the acute and chronic phases.
引用
- Ten Cate V, Rapp S, Schulz A, et al. Circulating microRNAs predict recurrence and death following venous thromboembolism. J Thromb Haemost. 2023. PMID: 37481073. doi:10.1016/j.jtha.2023.07.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。